Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: Information of primary antibodies used in the present study.

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques:

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: Primer sequence and promoter primer sequence.

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Sequencing

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: CD147 overexpression correlates with poor prognosis and RAP1 co-expression in colorectal cancer. ( A , B ) CD147 mRNA expression levels in tumor vs. normal tissues across multiple cancers (UCSC Xena database) and specifically in colorectal cancer (CRC) (GEPIA database). ** P < 0.01, unpaired t-test. ( C ) Kaplan-Meier survival analysis of CRC patients stratified by CD147 expression (log-rank test, P < 0.05). ( D ) Representative immunohistochemical images from The Human Protein Atlas showing CD147 expression in normal colorectal tissue (negative) and CRC tissue (cytoplasmic/membrane staining). ( E , F ) Western blot analysis of CD147 protein levels in paired CRC and adjacent normal tissues ( n = 12). β-actin served as loading control. *** P < 0.001, paired t-test. Origin blots are presented in Supplementary Fig. 1. ( G , H ) Correlation analyses between CD147 and RAP1A/B mRNA expression using GEPIA (Pearson’s correlation, P < 0.05) and TIMER2.0 (no significant correlation). ( I ) qRT-PCR validation of CD147 and Rap1 expression correlation in 12 CRC tissues (Pearson’s correlation, P < 0.01).

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Over Expression, Expressing, Immunohistochemical staining, Membrane, Staining, Western Blot, Control, Quantitative RT-PCR, Biomarker Discovery

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: CD147 expression validation and knockdown efficiency in CRC cell lines. ( A ) Immunofluorescence staining of CD147 in SW620 cells showing strong cytoplasmic expression (red) with partial membrane localization. Nuclei were counterstained with Hoechst 33,342 (blue). Scale bar: 30 μm. ( B ) Western blot analysis of CD147 protein levels in HCT116, SW620, and normal colon epithelial HCoEpiC cells. β-actin served as loading control ( n = 3 independent experiments). Original blots are presented in Supplementary Fig. 1. ( C ) qRT-PCR quantification of CD147 mRNA levels normalized to β-actin ( n = 3 independent experiments). ( D - F ) Lentiviral shRNA-mediated CD147 knockdown in HCT116 cells. ( D ) Representative Western blot of CD147 protein levels after transfection with three shRNAs (shCD147-1/2/3) or non-targeting control (shNC). Original blots are presented in Supplementary Fig. 1. ( E ) Densitometric quantification of CD147 protein expression from three independent experiments. ( F ) qRT-PCR analysis of CD147 mRNA levels post-knockdown (normalized to β-actin). Data are mean ± SD; *** P < 0.001 (Student’s t-test).

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Expressing, Biomarker Discovery, Knockdown, Immunofluorescence, Staining, Membrane, Western Blot, Control, Quantitative RT-PCR, shRNA, Transfection

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: CD147 knockdown inhibits proliferation and induces apoptosis in CRC cells. ( A ) CCK-8 proliferation assay showing reduced viability of HCT116 and SW620 cells transfected with shCD147-1 (shCD147) compared to non-targeting control (shNC) at 48 h and 72 h ( n = 3, mean ± SD; *** P < 0.001, one-way ANOVA). ( B , C ) Colony formation assay in shCD147 and shNC groups. ( B ) Representative images of colonies (crystal violet staining). ( C ) Quantification of colony numbers ( n = 3; *** P < 0.001 vs. shNC, Student’s t-test). ( D - F ) Western blot analysis of proliferation/apoptosis-related proteins. ( D ) Representative blots of c-Myc, Bcl-2, and Bax in shCD147 and shNC groups. β-actin served as loading control. Original blots are presented in Supplementary Fig. 2. ( E , F ) Densitometric quantification of protein levels ( n = 3; ** P < 0.01, *** P < 0.001 vs. shNC, Student’s t-test). ( G , H ) Flow cytometry analysis of apoptosis. ( G ) Representative Annexin V-FITC/PI staining profiles. ( H ) Quantification of apoptotic cell percentages ( n = 3; *** P < 0.001 vs. shNC, Student’s t-test).

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Knockdown, CCK-8 Assay, Proliferation Assay, Transfection, Control, Colony Assay, Staining, Western Blot, Flow Cytometry

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: CD147 knockdown suppresses migration, invasion, and epithelial-mesenchymal transition (EMT) in colorectal cancer cells. ( A , B ) Scratch wound healing assay in HCT116 and SW620 cells. ( A ) Representative images of wound closure at 24 h and 48 h post-scratching. ( B ) Quantification of wound closure rate ( n = 3; mean ± SD; ** P < 0.01, *** P < 0.001, vs. shNC, one-way ANOVA). ( C , D ) Transwell migration and invasion assays. ( C ) Representative images of migrated/invaded cells (crystal violet staining). ( D ) Quantification of migrated/invaded cells ( n = 3; *** P < 0.01 vs. shNC, Student’s t-test). ( E , F ) Western blot analysis of EMT-related proteins. ( E ) Representative blots of E-cadherin and N-cadherin in shCD147 and shNC groups. β-actin served as loading control. Original blots are presented in Supplementary Fig. 2. ( F ) Densitometric quantification of protein levels ( n = 3; ** P < 0.01, *** P < 0.001 vs. shNC, Student’s t-test).

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Knockdown, Migration, Wound Healing Assay, Staining, Western Blot, Control

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: Rap1 overexpression reverses the expression of key proteins in CD147 knockdown mediated cell proliferation, apoptosis and EMT. ( A , B ) Western blot analysis of Rap1 and Rap1GAP protein levels in HCT116 and SW620 cells after CD147 knockdown (shCD147). β-actin served as a loading control. Data represent mean ± SD ( n = 3; ** P < 0.01, *** P < 0.001 vs. shNC, Student’s t-test). Original blots are presented in Supplementary Fig. 3. ( C ) qRT-PCR validation of Rap1 mRNA overexpression in CD147-knockdown cells. Expression normalized to β-actin ( n = 3; *** P < 0.001 vs. HCT116 or SW620, Student’s t-test). ( D , E ) Western blot analysis of c-Myc, Bcl-2, Bax, N-cadherin, and E-cadherin protein levels in CD147-Knockdown cells with Rap1 overexpression ( n = 3; * P < 0.05, ** P < 0.01, *** P < 0.001 vs. shNC, # P < 0.05, ## P < 0.01, ### P < 0.001 vs. shCD147, one-way ANOVA). Original blots are presented in Supplementary Fig. 4.

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Over Expression, Expressing, Knockdown, Western Blot, Control, Quantitative RT-PCR, Biomarker Discovery

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: Rap1 overexpression rescues the regulatory effects of CD147 knockdown on proliferation and apoptosis. ( A ) CCK-8 assay showing proliferation of HCT116 ( n = 3; *** P < 0.001 vs. shNC, ### P < 0.001 vs. shCD147, one-way ANOVA). ( B , C ) Colony formation assays in HCT116 cells. Colonies were counted and normalized to shCtrl ( n = 3; ** P < 0.01, *** P < 0.001 vs. shNC, ### P < 0.001 vs. shCD147, one-way ANOVA). ( D , E ) Flow cytometry analysis of apoptosis in HCT116 cells. Percentages of apoptotic cells are shown ( n = 3; * P < 0.05 vs. shNC, # P < 0.05 vs. shCD147, one-way ANOVA). Similar results were observed in SW620 cells.

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Over Expression, Knockdown, CCK-8 Assay, Flow Cytometry

Journal: Scientific Reports

Article Title: CD147 regulates the Rap1 signaling pathway to promote proliferation, migration, and invasion, and inhibit apoptosis in colorectal cancer cells

doi: 10.1038/s41598-025-98266-8

Figure Lengend Snippet: Rap1 restores CD147-mediated migration and invasion in colorectal cancer cells. ( A , C ) Scratch wound healing assay in HCT116 cells. Healing rates were quantified at 24 h and 48 h ( n = 3; *** P < 0.001 vs. shNC, ## P < 0.01, ### P < 0.001 vs. shCD147, one-way ANOVA). ( B , D ) Transwell migration and Matrigel invasion assays. Migrated/invaded cells were counted and normalized to shCtrl ( n = 3; *** P < 0.001 vs. shNC, ### P < 0.001 vs. shCD147, one-way ANOVA). SW620 cells showed consistent trends. ( E ) Mechanistic diagram of CD147 promoting tumor progression through Rap1/Rap1GAP signaling in colorectal cancer cells.

Article Snippet: Anti CD147 mouse monoclonal antibody , 66443-1-AP , ProteinTech Group, Inc. , 1:5000 /1:200.

Techniques: Migration, Wound Healing Assay

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: (A) NF-kB activity in Hek-p65-luc cells transfected with human SOD1 WT , SOD1 G93A , or empty plasmid (mock) for 48h and treated with 0.5nM PPIA during the last 24h. Data are mean±SEM of n=3-4 independent experiments. Two-Way Anova followed by Tukey’s multiple comparisons test. (B) NF-kB activity in Hek-p65-luc cells transfected with siRNA control (siCTR) or against EMMPRIN (siEMN) for 72h, including 48h transfection with human SOD1 WT or SOD1 G93A and 24h treatment with 0.5nM PPIA. Data are mean±SEM of n=5 independent experiments. Two-Way Anova followed by Bonferroni’s multiple comparisons test. (C) NF-kB activity in Hek-p65-luc cells transfected with human SOD1 WT or SOD1 G93A plasmids for 48h and treated with a combination of 0.5nM PPIA and 0.5nM of control (CTR Ab) or anti-EMMPRIN (EMN Ab) antibody for the last 24h. Data are mean±SEM of n=3-4 independent experiments. Two-Way Anova followed by Tukey’s multiple comparisons test. For all experiments: All data were obtained by luciferase assay. Data are expressed as fold of Mock untreated cells. Relative luminescence units (RLU) were normalized on total proteins (TP, μg); *, p<0.05; **, p<0.01; ***, p<0.001.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Activity Assay, Transfection, Plasmid Preparation, Control, Luciferase

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: (A-D) Representative western blot of (A) lysates from 72h transfected Hek cells expressing human SOD1 WT , SOD1 G93A , or empty plasmid (mock) and relative quantification of PPIA (B) , low-glycosylated (37kDa) (C) and high-glycosylated (50kDa) (D) forms of EMMPRIN (EMN). Data are mean±SEM of n=3 independent experiments. One-Way Anova followed by uncorrected Fisher’s LSD test. (E-G) Representative western blot of (E) media from 72h transfected Hek cells expressing human SOD1 WT , SOD1 G93A , or empty plasmid (mock) and relative quantification of extracellular PPIA (ePPIA) (F) and soluble EMMPRIN (sEMN) (G) . Data are mean±SEM of n=3-4 independent experiments. One-Way Anova followed by uncorrected Fisher’s LSD test. (H) Luciferase assay for NF-kB activity in Hek-p65-luc cells transfected with human SOD1 WT or SOD1 G93A plasmids for 72h and treated with 0.5nM of control (CTR Ab) or anti-EMMPRIN (EMN Ab) antibody for the last 24h. Data are mean±SEM of n=3 independent experiments expressed as fold of Mock untreated cells. Two-Way Anova followed by Tukey’s multiple comparisons test. For all experiments: Target protein intensity was normalized on total transferred proteins (TTP). Relative luminescence units (RLU) were normalized on total proteins (TP, μg). *, p<0.05; **, p<0.01, ***, p<0.001.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Western Blot, Transfection, Expressing, Plasmid Preparation, Quantitative Proteomics, Luciferase, Activity Assay, Control

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: (A) Representative western blot and relative quantification of the high-glycosylated (50kDa) (B) and the low-glycosylated (37kDa) (C) forms of EMMPRIN (EMN) in the ventral horns of the lumbar spinal cord of Ntg (black dots) and SOD1 G93A (red dots) mice. Two-Way Anova: HG-EMN (interaction, p=0.084; age, p<0.0001; genotype, p<0.0001) followed by T-test for genotype comparison: HG-EMN (PS, p=0.4986; ON, **, p=0.0064; SY, ***, p=0.0005; ES, **, p=0.0052); LG-EMN (interaction, p=0.6868; age, p=0.825; genotype, p=0.831). One-Way Anova for linear trend: HG-EMN, p<0.0001; LG-EMN, p=0.0636. Target protein intensity was normalized on total transferred proteins (TTP). Data are mean±SEM of n=5 mice/stage. (D) Representative image of EMMPRIN (EMN, gray) expression in neuronal cells (NeuN, green) in the ventral horn of the lumbar spinal cord of NTg and SOD1 G93A mice at the onset of the disease. Large neurons, i.e motoneurons, are labeled by anti-EMMPRIN antibody. Experiments have been performed in n=3 mice/group. (E) Representative image of EMMPRIN (EMN, gray) expression in astrocytes (GFAP, green) in the ventral horn of the lumbar spinal cord of NTg and SOD1 G93A mice at an advanced symptomatic stage. (F) Representative image of EMMPRIN (EMN, gray) expression in microglia (Iba1, red) in the ventral horn of the lumbar spinal cord of NTg and SOD1 G93A mice at an advanced symptomatic stage. Of note, E and F are the same image but with split channels and performed appropriate merge. (G) Relative quantification of the percentage of astrocytes (GFAP) or microglia (Iba1) expressing EMMPRIN. Two-Way Anova (interaction, p=0.0003; age, p<0.0001; cell type, p<0.0001) followed by Bonferroni multiple comparison test for cell type comparison (***PS, p=0.0001; ON, SY, ES ****, p<0.0001). One-Way Anova for linear trend: GFAP, p<0.0001; Iba1, p<0.0001. Data are mean±SEM of n=4-5 mice/stage. For all experiment: PS, presymptomatic; ON, onset; SY, symptomatic; ES, end-stage. For D-F scale bar = 100μm.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Western Blot, Quantitative Proteomics, Comparison, Expressing, Labeling

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: (A) Representative image of primary cultures of NTg and SOD1 G93A astrocytes. Most of the cells present in the preparation are astrocytes (GFAP), and only a very small percentage of microglia (Iba1) cells is detected. Scale bar = 100μm. (B) Representative western blot and (C) relative quantification of EMMPRIN (EMN) in NTg astrocytes treated 24h with 0.5nM recombinant PPIA. Data are mean±SEM of n=3 independent experiments (dots) expressed as fold of NTg cells. Target protein intensity was normalized on total transferred proteins (TTP). *, p<0.05 by unpaired T-Test. (D) Relative quantification of factors released by NTg astrocytes after 24h of treatment with 0.5nM recombinant PPIA (N:P) compared to untreated NTg astrocytes (N:U). Red (upregulated), black (unchanged), blue (downregulated). Pooled media of n=5 preparations in duplicate. Data are expressed as fold of NTg untreated cells (N:U). *, p<0.05 versus untreated NTg astrocytes by unpaired T-Test. Relative fold change, p-value, difference and q-value are listed in Supplementary Table 1. (E) Pie chart of upregulated, unchanged or downregulated proteins in NTg astrocytes treated with PPIA compared to untreated NTg astrocytes. (F) Significant leading pathways related to the 43 upregulated proteins found in NTg astrocytes treated with PPIA. Proteins associated with the pathways are listed in Supplementary Table 2.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Western Blot, Quantitative Proteomics, Recombinant

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: Relative quantification of extracellular PPIA (ePPIA) (A) , EMMPRIN (EMN) (B) and the phosphorylated form pf p65/NF-kB (p-p65) (C) in NTg and SOD1 G93A astrocytes. Data are mean±SEM of n=3 independent experiments (dots) expressed as fold of NTg cells. Target protein intensity was normalized on total transferred proteins (TTP). *, p<0.05, **, p<0.01 by unpaired T-Test. (D) Relative quantification of factors released in 24h conditioned medium from SOD1 G93A astrocytes (G:U) compared to NTg astrocytes (N:U). Red (upregulated), black (unchanged), blue (downregulated). Pooled media of n=5 preparations in duplicate. Data are expressed as fold of Ntg untreated cells (N:U). *, p<0.05 versus untreated NTg astrocytes by unpaired T-Test. Relative fold change, p-value, difference and q-value are listed in Supplementary Table 3. (E) Pie chart of upregulated, unchanged or downregulated proteins in SOD1 G93A astrocytes compared to untreated NTg astrocytes. (F) Venn diagram showing 42 commonly secreted proteins between NTg astrocytes treated with PPIA (N:P) and SOD1 G93A astrocytes untreated (G:U). List of common proteins is present in Supplementary Table 4. (G) Significant leading pathways related to the 62 upregulated proteins found in SOD1 G93A astrocytes. Pathways found also in NTg astrocytes treated with PPIA are labelled with a star. Proteins associated with the pathways are listed in Supplementary Table 5.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Quantitative Proteomics

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: Relative quantification of extracellular PPIA (ePPIA) (A) , EMMPRIN (EMN) (B) and the phosphorylated form pf p65/NF-kB (p-p65) (C) in SOD1 G93A astrocytes treated 24h with 0.5nM anti-EMMPRIN (EMN Ab) or isotype control (CTR Ab) antibodies. Data are mean±SEM of n=3-4 independent experiments (dots) expressed as fold of NTg cells. Target protein intensity was normalized on total transferred proteins (TTP). *, p<0.05, **, p<0.01, ***, p<0.001 by unpaired T-Test. (D) Relative quantification of the 42 commonly secreted factors between untreated SOD1 G93A and NTg astrocytes treated with PPIA (List in Supplementary Table 4) released from SOD1 G93A astrocytes after 24h treatment with 0.5nM anti-EMMPRIN (G:E) or isotype control (G:C) antibodies. Red (upregulated), black (unchanged), blue (downregulated). Pooled media of n=4 preparations in duplicate. Data are expressed as fold of Ntg untreated cells (N:U). *, p<0.05; ** versus SOD1 G93A astrocytes treated with control antibody by unpaired T-Test. Relative fold change, p-value, difference and q-value are listed in Supplementary Table 6. (E) Pie chart of upregulated, unchanged or downregulated proteins in SOD1 G93A astrocytes treated with anti-EMMPRIN compared to control antibody treated SOD1 G93A astrocytes. (F) Significant leading pathways related to the 30 downregulated proteins found in SOD1 G93A astrocytes after anti-EMMPRIN treatment. Proteins associated with the pathways are listed in Supplementary Table 7.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Quantitative Proteomics, Control

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: (A) NF-kB activity in Hek-p65-luc cells transfected with human TDP-43 WT , TDP-43 A315T , or empty plasmid (mock) for 48h and treated with 0.5nM PPIA during the last 24h. Data are mean±SEM of n=6-8 independent experiments. Two-Way Anova followed by Tukey’s multiple comparisons test. (B) NF-kB activity in Hek-p65-luc cells transfected with siRNA control (siCTR) or against EMMPRIN (siEMN) for 72h, including 48h transfection with human TDP-43 WT or TDP-43 A315T and 24h treatment with 0.5nM PPIA. Data are mean±SEM of n=3 independent experiments. Two-Way Anova followed by Bonferroni’s multiple comparisons test. (C) NF-kB activity in Hek-p65-luc cells transfected with human TDP-43 WT or TDP-43 A315T plasmids for 48h and treated with a combination of 0.5nM PPIA and 0.5nM of control (CTR Ab) or 0.5nM anti-EMMPRIN (EMN Ab) antibody for the last 24h. Data are mean±SEM of n=3-6 independent experiments. Two-Way Anova followed by Tukey’s multiple comparisons test. For all experiments: All data were obtained by luciferase assay. Data are expressed as fold of Mock untreated cells. Relative luminescence units (RLU) were normalized on total proteins (TP, μg); *, p<0.05; **, p<0.01; ***, p<0.001.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Activity Assay, Transfection, Plasmid Preparation, Control, Luciferase

Journal: bioRxiv

Article Title: Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS

doi: 10.1101/2025.02.23.639749

Figure Lengend Snippet: Representative dot blot (A) and relative quantification ( B) of extracellular PPIA in the CSF of Ntg and TDP-43 A315T mice. One-Way Anova followed by Tukey’s multiple comparison test. *, p=0.0248. One-Way Anova for linear trend in TDP-43 A315T mice: p=0.1466. Representative western blot ( C ) and relative quantification of the high-glycosylated (50kDa) (D) and the low-glycosylated (37kDa) (E) forms of EMMPRIN (EMN) in the lumbar spinal cord of Ntg and TDP-43 A315T mice. One-Way Anova followed by Tukey’s multiple comparison test. **, p=0.0020; ***, p=0.0001. One-Way Anova for linear trend in TDP-43 A315T mice: HG-EMN, p=0.0051; LG-EMN, p=0.0054. For A-E, target protein intensity was normalized on total transferred proteins (TTP). Data are mean±SEM of n=3-4 mice/stage (6 months, onset; 10 months, early symptomatic; 13 months, late-symptomatic). (F) Representative image of EMMPRIN (EMN, gray) expression in neuronal cells (NeuN, green) in the ventral horn of the lumbar spinal cord of NTg and TDP-43 A315T mice at the onset of the disease (6 months). Large neurons, i.e motoneurons, are labeled by anti-EMMPRIN antibody. (G) Representative image of EMMPRIN (EMN, green) expression in astrocytes (GFAP, red) or microglia (Iba1, gray) in the ventral horn of the lumbar spinal cord of TDP-43 A315T mice at the early symptomatic stage (10 months). Please note that due to antigen retrieval we observed some Iba1 leaking signal in neurons (yellow arrow heads). For F, G: experiments have been performed in n=3 mice/group. Scale bar = 100μm.

Article Snippet: Antibodies used for immunoblot, (western/dot blot) (IB), immunofluorescence (IF) are as follows: rat monoclonal anti-EMMPRIN antibody (1:1000 for IB; 1:500 for IF; Bio-Rad, #MCA2283), rabbit polyclonal anti-EMMPRIN antibody (1:1000 for IB; ProteinTech, #11989-1-AP), rabbit polyclonal anti-PPIA antibody (1:5000 for IB; ProteinTech, #10720-1-AP), rabbit polyclonal anti-NF-kB p65 subunit antibody (1:1000 for IB; Santa Cruz Biotechnology, #sc-8008), rabbit polyclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3033), mouse monoclonal anti-phospo-NF-kB p65 (Ser536) antibody (1:1000 for IB; Cell Signaling Technology, #3036), rabbit polyclonal anti-Iba-1 antibody (1:500 for IF; Wako, #019-19741), mouse monoclonal anti-GFAP antibody (1:500 for IF; Cell Signaling Technology, #3670), mouse monoclonal anti-PPIA antibody (1:500 for IF; Invitrogen, #39-1100), rabbit monoclonal anti-NeuN antibody (1:500 for IF; Cell Signaling Technology, #12943), goat polyclonal anti-choline acetyltransferase antibody (1:500 for IF; Millipore, #AB114P), goat anti-mouse, anti-rabbit or anti-rat peroxidase-conjugated secondary antibodies (1:5000 for IB; Jackson Immunoresearch Lab), goat Alexa Fluor 647 or 555 or 488 anti-mouse or anti-rabbit or anti-rat or anti-goat fluorophore-conjugated secondary antibodies (1:500 for IF; Invitrogen).

Techniques: Dot Blot, Quantitative Proteomics, Comparison, Western Blot, Expressing, Labeling

Journal: eNeuro

Article Title: Preconditioning-Induced Facilitation of Lactate Release from Astrocytes Is Essential for Brain Ischemic Tolerance

doi: 10.1523/ENEURO.0494-23.2024

Figure Lengend Snippet: Upregulation of molecules related to lactate release in astrocytes after preconditioning (PC). Representative immunohistochemical images of the striatum stained with anti-glial fibrillary acidic protein (GFAP; green) and anti-monocarboxylate transporter (MCT) 1 (red), anti-MCT4 (red), or anti-CD147 (red) antibodies. Three days after PC (15 min of middle cerebral artery occlusion), MCT1 and MCT4, but not CD147, were expressed in GFAP-positive astrocytes in the contralateral striatum. Compared with those in the contralateral striatum, astrocytes in the ipsilateral striatum had markedly increased MCT1, MCT4, and CD147. Scale bars: main images, 20 µm; insets, 8 µm.

Article Snippet: Next, the sections were incubated for 3 d at 4°C with the following primary antibodies: rabbit anti-glial fibrillary acidic protein (GFAP; 1:1,000; Millipore), mouse anti-MCT1 (1:250; Abcam), mouse anti-MCT4 (1:50; Santa Cruz Biotechnology), or mouse anti-CD147 (1:50; Santa Cruz Biotechnology).

Techniques: Immunohistochemical staining, Staining

Journal: eNeuro

Article Title: Preconditioning-Induced Facilitation of Lactate Release from Astrocytes Is Essential for Brain Ischemic Tolerance

doi: 10.1523/ENEURO.0494-23.2024

Figure Lengend Snippet: P2X7 receptor agonist treatment upregulated CD147 in cultured astrocytes. Primary astrocyte cultures were treated with various concentrations of the P2X7 receptor agonist BzATP for 24 h at the indicated concentrations. Western blotting was then performed. Protein levels of HIF-1α and its target gene CD147 were significantly increased by BzATP treatment. In contrast, monocarboxylate transporter (MCT) 1 and MCT4 protein levels were unchanged by BzATP treatment. Data are representative of four independent experiments. The levels of these proteins were normalized to those of β-actin. Data show the fold increase over controls (no treatment). Values are shown as mean ± SEM; * p < 0.05, ** p < 0.01 versus control, one-way ANOVA followed by Dunnett's post hoc multiple-comparisons test; n = 4.

Article Snippet: Next, the sections were incubated for 3 d at 4°C with the following primary antibodies: rabbit anti-glial fibrillary acidic protein (GFAP; 1:1,000; Millipore), mouse anti-MCT1 (1:250; Abcam), mouse anti-MCT4 (1:50; Santa Cruz Biotechnology), or mouse anti-CD147 (1:50; Santa Cruz Biotechnology).

Techniques: Cell Culture, Western Blot

Journal: eNeuro

Article Title: Preconditioning-Induced Facilitation of Lactate Release from Astrocytes Is Essential for Brain Ischemic Tolerance

doi: 10.1523/ENEURO.0494-23.2024

Figure Lengend Snippet: Preconditioning (PC)-evoked and CD147-mediated increase in extracellular lactate levels during severe ischemia. One microliter of anti-CD147 (1 mg/ml) or its isotype control (1 mg/ml) was stereotaxically microinjected into the lateral ventricle of the brain 2 d after PC [15 min of middle cerebral artery occlusion (MCAO)]. The PC-evoked increase in extracellular lactate levels during severe MCAO (1 h of MCAO) was suppressed by anti-CD147. Data show the fold increase over control (naive) mice. Values are shown as mean ± SEM; ** p < 0.01, unpaired two-tailed Student's t test; n = 4–5.

Article Snippet: Next, the sections were incubated for 3 d at 4°C with the following primary antibodies: rabbit anti-glial fibrillary acidic protein (GFAP; 1:1,000; Millipore), mouse anti-MCT1 (1:250; Abcam), mouse anti-MCT4 (1:50; Santa Cruz Biotechnology), or mouse anti-CD147 (1:50; Santa Cruz Biotechnology).

Techniques: Two Tailed Test

Journal: eNeuro

Article Title: Preconditioning-Induced Facilitation of Lactate Release from Astrocytes Is Essential for Brain Ischemic Tolerance

doi: 10.1523/ENEURO.0494-23.2024

Figure Lengend Snippet: Inhibition of preconditioning (PC)-induced ischemic tolerance by CD147-blocking antibody. a , One microliter of anti-CD147 (1 mg/ml) or its isotype control (1 mg/ml) was stereotaxically microinjected into the lateral ventricle of the brain 2 d after PC [15 min of middle cerebral artery occlusion (MCAO)]. PC caused no damage. Furthermore, anti-CD147 injection after PC had no effect on TTC staining. Scale bar, 2 mm. b , One hour of MCAO-induced severe injury (mainly in the striatum and cortex) and was used to assess MCAO-induced brain injury (termed severe MCAO). c , Severe MCAO-evoked damage in the striatum was significantly reduced when mice received PC 3 days before experiencing severe MCAO. However, this ischemic tolerance was almost abolished when mice were injected with anti-CD147. The results are summarized in d . Values are shown as mean ± SEM; * p < 0.05, unpaired two-tailed Student's t test; n = 4–6.

Article Snippet: Next, the sections were incubated for 3 d at 4°C with the following primary antibodies: rabbit anti-glial fibrillary acidic protein (GFAP; 1:1,000; Millipore), mouse anti-MCT1 (1:250; Abcam), mouse anti-MCT4 (1:50; Santa Cruz Biotechnology), or mouse anti-CD147 (1:50; Santa Cruz Biotechnology).

Techniques: Inhibition, Blocking Assay, Injection, Staining, Two Tailed Test

Journal: eNeuro

Article Title: Preconditioning-Induced Facilitation of Lactate Release from Astrocytes Is Essential for Brain Ischemic Tolerance

doi: 10.1523/ENEURO.0494-23.2024

Figure Lengend Snippet: Schematic diagram of the mechanisms underlying preconditioning (PC)-induced ischemic tolerance. PC-evoked astrocytic activation induces CD147 expression via the P2X7 receptor/HIF-1α signaling pathway. This CD147 expression assists with the translocation of monocarboxylate transporter (MCT) 1 and MCT4 to the cell membrane, thereby promoting lactate release from astrocytes during severe ischemia; this effect likely plays a role in ischemic tolerance.

Article Snippet: Next, the sections were incubated for 3 d at 4°C with the following primary antibodies: rabbit anti-glial fibrillary acidic protein (GFAP; 1:1,000; Millipore), mouse anti-MCT1 (1:250; Abcam), mouse anti-MCT4 (1:50; Santa Cruz Biotechnology), or mouse anti-CD147 (1:50; Santa Cruz Biotechnology).

Techniques: Activation Assay, Expressing, Translocation Assay, Membrane

Journal: eNeuro

Article Title: Preconditioning-Induced Facilitation of Lactate Release from Astrocytes Is Essential for Brain Ischemic Tolerance

doi: 10.1523/ENEURO.0494-23.2024

Figure Lengend Snippet: P2X7 receptor agonist evoked the membrane translocation of monocarboxylate transporter (MCT) 1 and MCT4 via CD147 in cultured astrocytes. a , Primary astrocyte cultures were treated with 10 µM of the P2X7 receptor agonist BzATP for 24 h. Immunocytochemistry was then performed. Representative immunocytochemical images of the cultured astrocytes stained with anti-MCT1 (red) or anti-MCT4 (red) antibodies are shown. BzATP treatment induced the translocation of MCT1 and MCT4 from the perinuclear region to the cell surface in cultured astrocytes. Scale bar, 20 µm. b , Primary astrocyte cultures were treated with 10 µM BzATP and 0.1 µg/ml anti-CD147 or its isotype control for 24 h. Membrane protein extraction and Western blotting were then performed. In cultured astrocytes, the membrane expression levels of MCT1 and MCT4 were significantly increased by BzATP treatment; however, these increases were suppressed by anti-CD147. Data are representative of four independent experiments. The levels of these proteins were normalized to those of Na + /K + -ATPase. Data show the fold increase over control (control IgG treatment). Values are shown as mean ± SEM; * p < 0.05, ** p < 0.01, two-way ANOVA followed by Tukey's post hoc multiple-comparisons test; n = 4.

Article Snippet: Next, the sections were incubated for 3 d at 4°C with the following primary antibodies: rabbit anti-glial fibrillary acidic protein (GFAP; 1:1,000; Millipore), mouse anti-MCT1 (1:250; Abcam), mouse anti-MCT4 (1:50; Santa Cruz Biotechnology), or mouse anti-CD147 (1:50; Santa Cruz Biotechnology).

Techniques: Membrane, Translocation Assay, Cell Culture, Immunocytochemistry, Staining, Protein Extraction, Western Blot, Expressing